Related Experiment Video
Updated: Jul 15, 2025
Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency
M A Andreu Crespo1, L Castro-Feijóo2, J I Labarta-Aizpún3
1Pharmacy Department, Hospital Germans Trias i Pujol, Badalona, Spain.
Insights
Weekly somatrogon is a cost-effective treatment for pediatric growth hormone deficiency (GHD) in Spain compared to daily growth hormone (GH-d). It offers a significant quality-adjusted life year (QALY) gain, making it a dominant therapeutic option.
Area of Science:
- Pharmacoeconomics
- Pediatric Endocrinology
- Health Technology Assessment
Background:
- Growth hormone deficiency (GHD) impacts pediatric growth and development.
- Daily growth hormone (GH-d) is a standard treatment, but adherence and administration can be challenging.
- Novel treatment options like weekly somatrogon aim to improve patient outcomes and convenience.
Purpose of the Study:
- To evaluate the cost-effectiveness of weekly somatrogon versus daily growth hormone (GH-d) in Spanish children with GHD.
- To assess the economic value of somatrogon from the perspective of the Spanish National Health System.
Main Methods:
- A Markov model was utilized to simulate treatment outcomes in prepubertal children with GHD.
- The model incorporated costs for hormones and monitoring from Spanish sources and utilities from existing literature.
- Assumptions were validated by Spanish clinical experts, with simulations extending to age 18.
Main Results:
- Deterministic analysis indicated somatrogon is cost-effective, with a cost per QALY gained of €19,259 and a 0.336 QALY gain.
- Probabilistic analysis showed somatrogon as the dominant treatment, with a 61% probability at a willingness to pay of €25,000 per QALY.
Conclusions:
- Weekly somatrogon presents a cost-effective alternative to daily growth hormone (GH-d) for pediatric GHD in Spain.
- Somatrogon demonstrates favorable economic and clinical value, supporting its use in this population.
Objective:
To analyze the cost-effectiveness of weekly somatrogon compared to daily growth hormones (GH-d) in the pediatric population of Spain with growth hormone deficiency (GHD).
Methods:
Markov model with two states (patients with or without GH-d or somatrogon treatment) in prepubertal children (3 to 11 years and 3 to 12 years in girls and boys, respectively) with GHD in isolation or as part of multiple pituitary hormone deficiency and without previous treatment, from the perspective of the National Health System. The simulation of the economic model ends at the age of 18. The costs of hormones and monitoring were obtained from Spanish sources. The utilities were obtained from the literature. Spanish clinical experts validated the assumptions of the model.
Results:
In the deterministic analysis, somatrogon would be cost-effective, compared to GH-d, with a cost per QALY (quality-adjusted life year) gained of €19,259 and a clinically relevant QALY gain (0.336). This result was confirmed in deterministic sensitivity analyses. According to the probabilistic analysis, somatrogon would be the dominant treatment, with a 61% probability of a willingness to pay of €25,000 per QALY gained.
Conclusion:
Compared to GH-d, somatrogon is cost-effective in the Spanish pediatric population with GHD.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:02Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:16Bioequivalence: Overview
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...